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Summary (Abstract) 
Background 
We tested the hypothesis that the new sepsis and septic shock definitions will change the 
epidemiology of sepsis due to differences in criteria by comparing old and new sepsis 
populations. 
Methods 
We used a high quality, national, intensive care (ICU) database of 654,918 consecutive 
admissions to 189 adult ICUs in England, from January 2011 to December 2015. Primary 
outcome was acute hospital mortality. We compared old (Sepsis-2) and new (Sepsis-3) 
incidence, outcomes, trends in outcomes, and predictive validity of sepsis and septic shock 
populations.  
Results 
From among 197,724 Sepsis-2 severe sepsis and 197,142 Sepsis-3 sepsis cases, we 
identified 153,257 Sepsis-2 septic shock and 39,262 Sepsis-3 septic shock cases. The 
extrapolated population incidence of Sepsis-3 sepsis and Sepsis-3 septic shock was 101.8 
and 19.3 per 100,000 person-years in 2015. Sepsis-2 severe sepsis and Sepsis-3 sepsis had 
similar incidence, similar mortality, and showed significant risk adjusted improvements in 
mortality over time. Sepsis-3 septic shock had a much higher APACHE II score, greater 
mortality, and no risk-adjusted trends in mortality improvement compared to Sepsis-2 septic 
shock. ICU admissions identified either as Sepsis-3 sepsis or septic shock and as Sepsis-2 
severe sepsis or septic shock had significantly greater risk adjusted odds of death compared 
to non-sepsis admissions (p<0.001). The predictive validity was greatest for Sepsis-3 septic 
shock.    
Conclusions 
In an ICU database, compared with Sepsis-2, Sepsis-3 identifies a similar sepsis population 
with 92% overlap and much smaller septic shock population with improved predictive validity. 
Key words:  sepsis, septic shock, intensive care, epidemiology, outcomes 
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Introduction 
In February 2016, a Task Force convened by the European Society of Intensive Care 
Medicine and the society of Critical Care Medicine published new definitions for sepsis and 
septic shock (Sepsis-3)1, 2. Major differences between the new (Sepsis-3)1, 2 and old (Sepsis-
2)3 definitions will alter sepsis and septic shock epidemiology. The new sepsis definitions 
abandoned systemic inflammatory response syndrome (SIRS) criteria as the starting point for 
identifying sepsis, equated Sepsis-3 sepsis to Sepsis-2 severe sepsis3 and, for the first time, 
provided specific criteria for operationalising the definitions. Organ dysfunction was 
operationalised using the total Sequential [Sepsis-related] Organ Failure Assessment (SOFA) 
score 1, 4 and explicit criteria were proposed to define septic shock, harmonising multiple 
criteria used in the literature2, 5. Understanding the impact of changes in definitions on 
updated sepsis epidemiology is necessary to inform clinical care, future research and health 
care planning. 
In this context, we tested the impact of the new sepsis definitions on epidemiology, by 
comparing Sepsis-2 severe sepsis/septic shock and Sepsis-3 sepsis/septic shock populations 
derived from the same high quality national ICU database that covers 96% of the adult 
general ICUs and combined ICU/high dependency units in England. We compared the 
incidence, deaths, ICU and general population extrapolations, annual trends, and predictive 
increment for acute hospital mortality of Sepsis-2 severe sepsis/septic shock and Sepsis-3 
sepsis/septic shock over a five year-period between January 2011 and December 2015.   
Methods 
Data source 
The Case Mix Programme is the national clinical audit for adult general ICUs in England. For 
consecutive admissions, trained data collectors collect sociodemographic, comorbidity, and 
physiologic data to precise rules and definitions, during the first 24 hours following admission 
to ICU. Diagnostic data are determined clinically and coded using the hierarchical Intensive 
Care National Audit & Research Centre (ICNARC) Coding Method6. Collected data undergo 
extensive local and central validation prior to pooling into the Case Mix Programme Database 
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(CMPD). Support for the collection and use of these data has been obtained under Section 
251 of the National Health Service Act 2006 (approval number: PIAG 2–10(f)/2005)7. 
Case definitions 
Our study evaluated sepsis and septic shock during the first 24 hours following ICU 
admission. Sepsis-2 severe sepsis and septic shock have been operationalised in several 
different ways, whereas Sepsis-3 provided specific criteria, which we followed as closely as 
possible. We identified presence of infection from the reported primary (mandated) and 
secondary (optional) reasons for ICU admission, derived SIRS criteria and organ dysfunctions 
(based on SOFA score) using raw physiological and laboratory data from the first 24 hours 
following ICU admission. For organs where the relevant physiology to define SOFA were not 
available, we derived organ dysfunction based on receipt of organ support, according to 
national Critical Care Minimum Dataset (CCMDS) definitions. As SOFA score categorises 
organ function from 0 (normal) to 4 (most abnormal)4, we used SOFA score>=1 as organ 
dysfunction to define Sepsis-2 severe sepsis as proposed by Levy et al (page 12533). Our 
operationalisations of the Sepsis-2 and Sepsis-3 definitions are described in Table-1. 
Analysis 
After describing the Sepsis-2 and Sepsis-3 populations, we compared the trends in incidence, 
mortality and predictive validity of Sepsis-3 sepsis and septic shock. As unmeasured 
physiology was <5% in all sepsis case definitions data fields, we assumed unmeasured 
physiology to be normal. The primary outcome was all-cause acute hospital mortality. As 
missing data was <0.5% for the primary outcome, we performed complete case analyses in 
regression models, assuming missing data were missing at random conditional on the model 
covariates.  
Trends in incidence and extrapolations 
We estimated the annual number of admissions to ICUs in England between January 2011 
and December 2015 with sepsis and septic shock (by Sepsis-2 and Sepsis-3 definitions) by 
extrapolating the actual numbers for participating ICUs to the total number of ICUs in England 
for each year, as reported previously7. We converted these extrapolated numbers to 
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population incidences (overall and by age categories and comorbidity status) using mid-year 
population estimates obtained from the Office for National Statistics8.  
Trends in and risk factors for acute hospital mortality 
We calculated unadjusted and adjusted trends in acute hospital mortality over the 5-year 
study period for sepsis and septic shock (by Sepsis-2 and Sepsis-3 definitions) using logistic 
regression. Risk-adjusted trends were compared using four separate logistic regression 
models that adjusted for admission year, age, sex, ethnicity, severe co-morbidity (defined 
according to Acute Physiology And Chronic Health Evaluation [APACHE] II 9), functional 
status, surgical status, illness severity (APACHE II acute physiology score9), and infection 
site7. 
Assessment of predictive validity 
We assessed the improvement in predictive validity both qualitatively, by comparing the 
difference in illness severity and mortality between the populations identified by Sepsis-2 and 
Sepsis-3, and quantitatively, using logistic regression models. For the logistic regression 
approach to be valid, the baseline model must use well-established risk predictors and 
outcomes as originally intended and the addition of the sepsis or septic shock category as a 
new predictor must improve model performance for the outcome predicted10. Thus, we 
derived a baseline model for acute hospital mortality, adjusted for admission year, age, sex, 
ethnicity, severe co-morbidity, functional status, surgical status and illness severity, using the 
overall population of all ICU admissions. Then we compared the additional odds of dying from 
sepsis/septic shock compared to the non-sepsis population (adjusted odds ratios (OR)) and 
the increment in model fit using change in area under the curve (∆-AUC), Bayesian 
Information Criterion (∆-BIC) and Brier Scores when adding sepsis and septic shock (by 
Sepsis-2 and Sepsis-3 definitions) as new binary predictors within nested models. 
Sensitivity analysis 
We performed two sensitivity analyses. First, we excluded patients with severe comorbidity, 
to account for change in SOFA score of 2 required for operationalising the Sepsis-3 criteria. 
The rationale for this analysis is that patients with comorbidity may have baseline organ 
dysfunction that could potentially contribute to SOFA score. Second, we reassessed all four 
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regression models of predictive validity without including illness severity (APACHE II acute 
physiology score). The rationale for this analysis is that including illness severity in our 
original analyses may mask the incremental change in discrimination provided by the 
presence of organ dysfunction to diagnose sepsis. 
All logistic regression models excluded readmissions of the same patient during the same 
hospital stay, used only admission day APACHE II acute physiology score for severity of 
illness adjustment (to avoid double weighting of organ dysfunction in models as the score 
includes respiratory, renal, hypotension and Glasgow coma score variables), were fitted with 
robust standard errors to account for clustering by ICU, and were reported as OR with 95% 
confidence intervals (CI). Reported p values are two sided and a p value less than 0.05 was 
considered a statistically significant result. Continuous data were summarized as mean and 
standard deviation (SD), where normally distributed, and median and interquartile range, 
where not. Categorical data were presented as frequency and percentage. All analyses were 
performed using Stata/SE Version 14.2 (StataCorp LP, College Station, TX). 
Results 
Descriptive comparison 
Over the 5-year study period, amongst 654,918 admissions to 189 adult general ICUs in 
England, there were 197,724 (30.2%) Sepsis-2 severe sepsis, 197,142 (30.1%) Sepsis-3 
sepsis cases (Table-2) and 449,295 non-sepsis admissions (eTable-1). Among the sepsis 
cases, 189,243 met both definitions (92.0% of those meeting either definition) with 4.1% of 
Sepsis-2 severe sepsis cases not meeting stricter organ dysfunction criteria for Sepsis-3 and 
4.0% of Sepsis-3 sepsis cases being SIRS negative. Amongst the sepsis admissions, there 
were 153,257 (77.5%) Sepsis-2 septic shock and 39,262 (19.9%) Sepsis-3 septic shock 
cases with 0.01% of Sepsis-3 septic shock cases being SIRS negative (Figure1). The 
distributions of age, sex, dependency status, ethnicity, presence of severe co-morbidity, 
surgical status, and admission source were comparable between cohorts. Respiratory was 
the most common infection site and organ dysfunction in all cohorts with comparable 
distributions of other infection sites and organ dysfunctions. The acute illness severity, serum 
lactate concentrations and hospital mortality were higher in septic shock cohorts, with 
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greatest severity in Sepsis-3 septic shock (Table-2; Figure-2). Sepsis patients identified only 
by Sepsis-3 were older, with greater illness severity (APACHE II score mean (SD) 15.1 (7.2) 
versus 9.7 (3.9)) and higher mortality (22.3% versus 7.0%), when compared to those patients 
identified only by Sepsis-2 (eTable-2). The incidence of, and mortality from, Sepsis-2 severe 
sepsis, Sepsis-2 septic shock, Sepsis-3 sepsis and Sepsis-3 septic shock increased with age 
(Figure-3). 
Trends in incidence 
The Sepsis-2 severe sepsis and Sepsis-3 sepsis accounted for a third of admissions to adult 
general ICUs in England over the 5-year period. The extrapolated population incidence 
increased similarly for both from 88 to 102 per 100,000 person-years. The Sepsis-2 septic 
shock and Sepsis-3 septic shock accounted 23.4% and 6.0% of admissions to adult general 
ICUs in England over the 5-year period. Sepsis-2 septic shock accounted for three quarters of 
the severe sepsis population and the extrapolated population incidence increased from 69 to 
79 per 100,000 person-years. In contrast, Sepsis-3 septic shock was only one fifth of the 
sepsis population and with minimal change in the extrapolated population incidence over the 
5-year period (approximately 19 per 100,000 person-years (eTable-3; Figure-4). 
Trends in, and risk factors for, acute hospital mortality 
The acute hospital mortality for Sepsis-2 severe sepsis and Sepsis-3 sepsis were similar and 
decreased from 33% in 2011 to 30% in 2015. The acute hospital mortality for Sepsis-2 septic 
shock decreased from 37% in 2011 to 33% in 2015. In contrast, the acute hospital mortality 
for Sepsis-3 septic shock changed from 57% in 2011 to 56% in 2015. The extrapolated 
numbers of deaths are shown in eFigure-1. The rate of improvement in unadjusted and risk-
adjusted acute hospital mortality was significant for Sepsis-2 severe sepsis, Sepsis-3 sepsis 
and for Sepsis-2 septic shock. In contrast, no statistically significant trends in unadjusted or 
risk-adjusted acute hospital mortality were observed for patients meeting the Sepsis-3 septic 
shock case definition (eTable-4).  
The independent risk factors for acute hospital mortality identified for Sepsis-3 sepsis and 
septic shock were, increasing age, male, presence of severe comorbidity, increasing 
dependency, and worsening APACHE II acute physiology score. Compared to the non-
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surgical group, surgical populations had lower risk of death. Compared to respiratory tract 
infections, gastrointestinal and genitourinary infections had lower risk of death (eTable-5; 
eTable-6). 
Assessment of predictive validity 
As shown in Figure-2, Sepsis-2 severe sepsis and Sepsis-3 sepsis are similar cohorts, but 
Sepsis-3 septic shock is more severe with a greater risk of death compared to Sepsis-2 septic 
shock. The population identified only by Sepsis-2 severe sepsis (SIRS-positive with 1 point on 
SOFA) had lower mortality compared to that identified only by Sepsis-3 sepsis (SIRS-
negative with 2 or more points on SOFA; 7.0% versus 22.4%; eTable-2). The additional OR 
(95%CI) of dying from Sepsis-3 sepsis compared to ICU admissions without sepsis was 1.16 
(1.13–1.20), which was similar to Sepsis-2 severe sepsis implying similar predictive validity. 
The additional OR (95%CI) of dying from Sepsis-3 septic shock compared to ICU admissions 
without sepsis was 2.44 (2.32–2.57), which is much higher than Sepsis-2 septic shock and 
Sepsis-3 sepsis implying a significantly better predictive increment with the Sepsis-3 septic 
shock diagnosis. The increment in AUC and BIC was greatest for Sepsis-3 septic shock, with 
a Brier score of 0.118 (Table-2). 
Sensitivity analysis 
The results of sensitivity analyses were consistent with the primary analyses. We observed 
improving trends risk-adjusted acute hospital mortality only in Sepsis-3 sepsis (OR/year (95% 
CI) 0.96 (0.94 – 0.97); p<0.001) and highest increment in predictive validity for Sepsis-3 
septic shock (OR (95% CI) 2.28 (2.11 – 2.47)) in patients without severe comorbidity.  The 
highest increment in predictive validity was for Sepsis-3 septic shock in the regression models 
without illness severity (eTable-7). 
Discussion 
In ICUs in England, Sepsis-2 severe sepsis and Sepsis-3 sepsis definitions identify similar 
cohorts with 92% overlap. Between 2011 and 2015, incidence increased and risk-adjusted 
acute hospital mortality improved. Sepsis-3 septic shock criteria identify a much smaller 
population compared to Sepsis-2 septic shock, with very little increase in incidence between 
2011 and 2015. When compared to non-sepsis admissions after risk adjustment, Sepsis-3 
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sepsis has 1.15 times, and Sepsis-3 septic shock 2.42 times, greater odds of death. The 
extrapolated population incidences of Sepsis-3 sepsis and septic shock in 2015 were 102 and 
19 per 100,000 person-years, respectively. The corresponding annual adult ICU caseloads in 
England in 2015 were 45,200 and 8,600 patients, respectively.  
The descriptive epidemiology of Sepsis-3 sepsis in ICU setting is similar to that described 
previously for Sepsis-2 severe sepsis 2, 7. The incidence and mortality of Sepsis-3 sepsis and 
septic shock increase significantly with age and comorbidity 11, 12. The overall frequency of 
Sepsis-3 septic shock (6 per 100 ICU admissions) was similar to previous reports in other 
ICU settings using ICD codes for estimating septic shock incidence between 1993 and 2000 2, 
13. The reduction in proportion of Sepsis-3 septic shock seen in our study is supported by the 
recently published secondary analysis of Vasopressin and Septic Shock Trial14. The 
increasing population incidence, and decreasing trends in mortality of Sepsis-3 sepsis are 
consistent with what we would expect from our previous Sepsis-2 publications 7, 15. Sepsis-3 
sepsis identifies SIRS positive and SIRS negative patients but with greater degree of organ 
dysfunction. The higher mortality in the population identified only by Sepsis-3 (eTable-1) is 
secondary to greater severity of illness, which is an example of predictive validity intended by 
Sepsis-3 definitions1, 16.  
We present one of the first direct comparisons of old and new sepsis epidemiology, using a 
high quality national ICU database with >90% potential ICU population coverage. We used 
primary or secondary reason for admission to identify infection, to maximise sensitivity for 
identifying sepsis cases. We operationalised old and new definitions using raw physiology 
data and used consecutive admissions over a five-year period between 2011 and 2015, 
overcoming the challenges often highlighted with using insurance claims or reimbursement 
formulae for reporting sepsis epidemiology 7, 17-19. Editorials have argued that abandoning 
SIRS may result in delayed identification of high risk sepsis population 20-22.  The rationale for 
abandoning SIRS criteria as the starting point of the nested sepsis illness model include lack 
of discriminant validity 1, 16, 23-25, occurrence of SIRS negative sepsis in the ICU setting 7, 26 
and well documented early immunosuppression in sepsis 27. From our analysis, in the UK ICU 
setting, abandoning SIRS as the starting point for sepsis diagnosis does not alter the 
incidence as most patients with organ dysfunction also tend to have SIRS. The population 
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identified by Sepsis-3 sepsis has a higher mortality, which is explained by greater burden of 
organ dysfunction when using SOFA>=2 points as criteria. Admittedly, our results from ICU 
settings in England are not applicable to resource limited settings2, sepsis in general wards28 
and in settings where there is established lactate screening as part of quality improvement 
initiatives29.  
Our study also has several limitations. Our study reports the epidemiology of adult ICU 
admissions with sepsis using data in the first 24 hours of ICU admission, which potentially 
underestimates incidence. As England has among the lowest per capita ICU bed provision in 
Europe (3.5 to 7.4 per 100,000 population)30, 31, probability of underestimation is low as organ 
dysfunction will often be present on admission day. We derived our organ dysfunction using a 
modified SOFA score, as not all physiological parameters were present in the dataset. 
Although, we did not use change in SOFA score due to lack of pre-admission organ 
dysfunction variables, we used the method recommended by the Sepsis-3 definitions paper 
for operationalising SOFA where baseline organ dysfunction is not available and performed 
sensitivity analysis to support our inferences1. Although we used a sensitive definition for 
Sepsis-2 septic shock that potentially overestimates the Sepsis-2 septic shock incidence, our 
operationalisation was used in three recent resuscitation trials32 and was a common 
operationalisation method in epidemiological studies of septic shock2. We do not have data 
on fluid resuscitation in all patients. However, the recently completed UK based early goal 
directed therapy trial 97% of patient received at least 2,000ml of fluid between hospitalisation 
and prior to randomisation33, implying that most patients in the study requiring inotropes 
would have received some form of resuscitation fluids. This assumption is also supported by 
the recent UK-wide National Confidential Enquiry Into Patient Outcome and Death report on 
sepsis, which highlighted 82.5% of patients received resuscitation fluids prior to critical care 
admission34. To partially account for these issues, we used the admission day APACHE II 
acute physiology score that contains components of organ dysfunction weighted in the 
regression models presented and used acute hospital mortality as primary outcome, which is 
what APACHE II score is calibrated for. All our regression models had AUC>0.75 and Brier 
scores<0.2, implying good model fit and performance 10.  Although the clinical care, the 
decision to accept patient for ICU care and changes in process of care could influence 
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incidence and outcomes over the study period, understanding the impact of these elements 
were not our study objectives and must be considered for future research. Despite the 
limitations, our study provides a conceptual framework for future work in this area. 
Our in-depth descriptive epidemiology of Sepsis-3 generates numerous fundamental 
analytical epidemiology questions. For example, Sepsis-3 sepsis focuses on organ 
dysfunction as core illness characteristic but interventional trials aimed at improving organ 
dysfunction have not consistently resulted in survival benefit 35, 36. We confirm that Sepsis-3 
septic shock is a high-risk of death population, which can be interpreted as better predictive 
validity and argued as prognostic enrichment resulting in potentially greater trial efficiency37. 
However, there is no proof that this cohort will necessarily have improved treatment response 
to trial interventions, which is predictive enrichment 37, 38. Thus, it is important to study the 
magnitude of risk reduction that is feasible in these populations, an essential component of 
future trial design. This updated epidemiology has implications for future trial design. 
Conclusions 
Our study shows that Sepsis-2 and Sepsis-3 definitions identified similar populations of 
sepsis cases with 92% overlap in ICU setting in England. Sepsis-3 also identifies a SIRS 
negative population and a much smaller septic shock subpopulation with a greater risk of 
death, which highlight improved predictive validity of the Sepsis-3 definitions. 
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Legends to tables and figures 
Table legends 
Table-1: Operationalisation of Sepsis-2 and Sepsis-3 Definitions 
The SIRS criteria are detailed in ESM methods section. For defining severe sepsis as per 
Sepsis-2 definitions, we followed the recommendations proposed by Levy et al and we 
treated SOFA score of 1 or more as organ dysfunction (page 1253 in Levy et al3). As the 
baseline organ dysfunction is unknown in our study cohort, we assumed the baseline organ 
dysfunction was zero, as recommended in the Sepsis-3 consensus definitions (page 805 in 
Singer et al1) and performed sensitivity analyses by excluding patients with pre-existing 
comorbidity. We used a modified SOFA score to generate organ dysfunction. We derived 
respiratory, renal, cardiovascular, haematological and neurological SOFA, as recommended 
by SOFA score categories and recoded them as 0, 1 or >= 2 for each organ system. 
Respiratory SOFA was derived using ratio of partial pressure of oxygen to inspired oxygen 
concentration (PaO2/FiO2). Renal SOFA was estimated using serum creatinine and/or urine 
output. Haematological SOFA score was estimated using platelet count. Neurological 
dysfunction was defined using Glasgow Coma Scale, with a score of 1 given for GCS 
between 13-14 and >=2 was for GCS <13 and/or sedated/paralysed for entire of first 24hours. 
As we did not have bilirubin to define hepatic dysfunction, we used receipt of advanced liver 
support and coded that as hepatic SOFA score of >=2. Advanced liver support is defined as 
acute on chronic hepatocellular failure requiring management of coagulopathy and/or portal 
hypertension (including liver purification and detoxification techniques). Cardiovascular 
dysfunction was derived as systolic blood pressure <90 mm Hg or mean arterial pressure <70 
mm Hg or need for vasopressors to maintain blood pressure, identified by receipt of 
advanced cardiovascular support. aFor defining Sepsis-2 septic shock, we operationalised the 
criteria used in the recent early goal directed therapy trials of hypotension or need for 
vasopressor therapy or serum lactate>4mmol/L32. aFor defining Sepsis-2 and Sepsis-3 septic 
shock, we used highest blood lactate post ICU admission and use of vasoactive drugs.  
 
Table-2: Case mix characteristics for admissions to adult general intensive care units 
in England with sepsis and septic shock (by Sepsis-2 and Sepsis-3 definitions) 
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Adjusted OR (95% CI)# refers to the additional risk of death due to sepsis or septic shock 
when compared to non-sepsis admissions using a fully adjusted logistic regression model. 
The regression models for Sepsis-3 sepsis and Sepsis-3 Septic shock are shown in eTable-4 
and eTable-5. We used a modified SOFA score to generate organ dysfunction (see Table-1). 
Abbreviations and explanations: SD=standard deviation; N=number; %=percentage; ED= 
Emergency department; ICU= intensive care unit; APACHE II= Acute Physiology and Chronic 
Health Evaluation II; ICNARC= Intensive Care National Audit & Research Centre; MDH= 
Musculoskeletal, Dermatological, Haematological; Serum lactate= highest serum lactate 
concentrations measured in blood in the first 24 hours of ICU admission; IQR= inter–quartile 
range; LOS = length of stay; OR = odds ratio; 95% CI = 95% Confidence intervals; p=p-value; 
AUC= Area under the receiver operating characteristic curve; Brier score is an aggregate 
measure of disagreement between the observed outcome and a model based prediction with 
a perfect prediction value of 0, a score of 0.25 for 50/50 prediction and a score of 0.2225 
equates to a p=0.65; DAUC refers to the comparison of AUC between the two models with 
and without sepsis/septic shock category.  |DBIC| refers to the absolute difference in 
Bayesian Information Criterion between the two models: first without sepsis/septic shock 
category and second with sepsis/septic shock category. A higher score points towards an 
improved regression model fit when adding the sepsis/septic shock variable. Any |DBIC| 
value>10 provides very strong support for the model when comparing model fits for the 
outcome. 
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Tables 
Table-1: Operationalisation of Sepsis-2 and Sepsis-3 Definitions 
 
Criteria Sepsis-2 Sepsis-3 
Infection Reason for ICU admission Reason for ICU admission 
SIRS positive Presence of two or more SIRS criteria Not applicable 
Organ dysfunction SOFA score of 1 or more in any one organ system 
SOFA score of 2 or more in any one organ system or SOFA 
score of 1 in two or more organ systems 
(Severe) sepsis Severe sepsis = 
Infection AND SIRS positive AND >=1 SOFA points 
Sepsis = 
Infection AND >=2 SOFA points 
Septic shocka Infection AND SIRS positive AND (cardiovascular SOFA>=1 
OR serum lactate concentration>=4mmol/L) 
Infection AND cardiovascular SOFA>=2 AND serum lactate 
concentration>2mmol/L 
 
  
  
19 
19 
Table-2: Case mix characteristics for admissions to adult general intensive care units in England with sepsis and septic shock (by Sepsis-2 and 
Sepsis-3 definitions) 
Parameter Sepsis-2 Severe Sepsis 
N=197,724 
Sepsis-3 Sepsis 
N=197,142 
Sepsis-2 Septic shock 
N= 153,257 
Sepsis-3 Septic shock 
N= 39,262 
Age in years mean (SD) 62.8 (17.2) 63.3 (16.9) 63.7 (16.9) 65.3 (15.0) 
Sex Female N (%) 89,923 (45.5%) 88,612 (45.0%) 71,078 (46.4%) 17,505 (44.6%) 
Ethnicity N (%) 
White 
Asian 
Black 
Other 
Mixed 
Not stated 
 
178,249 (90.2%) 
7,536 (3.8%) 
4,459 (2.3%) 
2,288 (1.25) 
920 (0.5%) 
4,272 (2.2%) 
 
177,829 (90.2%) 
7,465 (3.8%) 
4,366 (2.2%) 
2,269 (1.2%) 
912 (0.5%) 
4,301 (2.2%) 
 
138,557 (90.4%) 
5,806 (3.8%) 
3,159 (2.1%) 
1,754 (1.1%) 
682 (0.5%) 
3,299 (2.2%) 
 
35,033 (89.2%) 
1,671 (4.3%) 
885 (2.3%) 
541 (1.4%) 
186 (0.5%) 
946 (2.4%) 
Dependency status N (%) 
No dependency 
Mild to Moderate 
Severe 
 
137,113 (69.4%) 
57,081 (28.9%) 
3,530 (1.8%) 
 
135,771 (69.9%) 
57,770 (29.3%) 
3,601 (1.8%) 
 
105,266 (68.7%) 
45,182 (29.5%) 
2,809 (1.8%) 
 
29,098 (71.6%) 
10,748 (27.4%) 
416 (1.1%) 
Past medical history N (%) 39,477 (20.0%) 39,917 (20.3%) 31,086 (20.4%) 8,156 (20.9%) 
Severe comorbidity N (%) 
Cardiovascular 
Respiratory 
Liver 
Renal 
Metastatic disease 
Hematologic 
Immunosuppressed 
 
2,717 (1.8%) 
5,855 (3.8%) 
3,866 (2.5%) 
3,173 (2.1%) 
4,104 (2.7%) 
5,889 (3.8%) 
13,331 (8.7%) 
 
3,380 (1.7%) 
8,331 (4.2%) 
4.690 (2.4%) 
4,282 (2.2%) 
4,961 (2.5%) 
7,236 (3.7%) 
16,828 (8.5%) 
 
2,717 (1.8%) 
5,855 (3.8%) 
3,866 (2.5%) 
3,173 (2.1%) 
4,104 (2.7%) 
5,889 (3.8%) 
13,331 (8.7%) 
 
712 (1.8%) 
1,090 (2.8%) 
1,291 (3.3%) 
806 (2.1%) 
1,098 (2.8%) 
1,664 (4.2%) 
3,551 (9.0%) 
Surgical status N (%) 
Non–surgical 
Elective surgical 
Emergency surgical 
 
145,725 (75.2%) 
8,659 (4.4%) 
40,324 (20.4%) 
 
149,718 (76.0%) 
8,219 (4.2%) 
39,191 (19.9%) 
 
115,325 (75.3%) 
6,210 (4.1%) 
31,722 (20.7%) 
 
29,276 (75.4%) 
861 (2.2%) 
9,135 (23.3%) 
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Admission source N (%) 
ED or not in hospital 
Theatre 
Ward in hospital   
Another ICU 
Another hospital 
 
45,451 (23.0%) 
48,983 (24.8%) 
88,393 (44.76%) 
13,299 (6.7%) 
1,582 (0.8%) 
 
45,633 (23.1%) 
47,410 (24.1%) 
88,968 (45.1%) 
14,529 (6.9%) 
1,588 (0.8%) 
 
37,244 (24.3%) 
37,932 (24.8%) 
67,310 (43.9%) 
9,589 (6.3%) 
1,182 (0.8%) 
 
10,887 (27.7%) 
9,996 (25.5%) 
15,926 (40.6%) 
2,181 (5.6%) 
280 (0.7%) 
Illness severity scores mean (SD) 
APACHE II Physiology 
APACHE II 
 
13.5 (5.9) 
18.2 (6.8) 
 
13.7 (5.9) 
18.5 (6.7) 
 
14.4 (5.9) 
19.2 (6.8) 
 
17.0 (6.5) 
22.0 (7.1) 
Infection source N (%) 
Respiratory 
Gastrointestinal 
Cardiovascular 
Genitourinary 
MDH 
Neurological 
Unknown 
 
97,682 (49.4%) 
52,022 (26.3%) 
4,240 (2.1%) 
13,127 (6.6%) 
10,710 (5.4%) 
5,817 (2.9%) 
14,126 (7.1%) 
 
98,785 (50.1%) 
50,799 (25.8%) 
4,264 (2.2%) 
12,796 (6.5%) 
10,499 (5.3%) 
5,815 (3.0%) 
14,185 (7.2%) 
 
72,615 (47.4%) 
40,977 (26.7%) 
3,510 (2.3%) 
10,923 (7.1%) 
8,783 (5.7%) 
3,933 (2.6%) 
12,516 (8.2%) 
 
16,541 (42.1%) 
12,310 (31.4%) 
1,121 (2.9%) 
2,388 (6.1%) 
1,968 (5.0%) 
605 (1.5%) 
4,329 (11.0%) 
SIRS status N (%) 
0 
1 
2 
3 
4 
 
0 
0 
37,613 (19.0%) 
84,759 (42.9%) 
75,352 (38.1%) 
 
894 (0.5%) 
7,005 (3.6%) 
34,963 (17.7%) 
80,987 (41.1%) 
73,293 (37.9%) 
 
0 
0 
26,741 (17.5%) 
64,649 (42.1%) 
61,867 (40.4%) 
 
33 (0.1%) 
333 (0.9%) 
3,875 (9.9%) 
14,905 (38.0%) 
20,116 (51.2%) 
Organ dysfunction N (%) 
Cardiovascular SOFA 
0 
1 
>=2 
Respiratory SOFA 
0 
1 
 
 
48,175 (24.4%) 
90,635 (45.8%) 
58,914 (29.8%) 
 
18,602 (9.4%) 
29,332 (14.8%) 
 
 
45,951 (23.3%) 
91,024 (46.2%) 
60,167 (30.5%) 
 
14,665 (7.4%) 
27,859 (14.1%) 
 
 
3,708 (2.4%) 
90,635 (59.1%) 
58,914 (38.4%) 
 
13,793 (9.0%) 
22,213 (14.5%) 
 
 
- 
- 
39,262 (100%) 
 
1,146 (2.9%) 
4,143 (10.6%) 
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>=2 
Renal SOFA 
0 
1 
>=2 
Haematological SOFA 
0 
1 
>=2 
Neurological SOFA 
0 
1 
>=2 
Hepatic SOFA# 
<2 
>=2 
149,770 (75.8%) 
 
97,036 (49.1%) 
33,926 (17.2%) 
66,762 (33.8%) 
 
139,258 (70.4%) 
28,870 (14.6%) 
29,596 (15.0%) 
 
98,488 (49.8%) 
27,679 (14.0%) 
71,557 (36.2%) 
 
195,573 (98.9%) 
2,151 (1.1%) 
154,618 (78.4%) 
 
93,428 (47.4%) 
34,656 (17.6%) 
69,058 (35.0%) 
 
136,985 (69.5%) 
29,842 (15.1%) 
30,315 (15.4%) 
 
95,286 (48.3%) 
28,147 (14.3%) 
73,709 (37.4%) 
 
194,946 (98.9%) 
2,196 (1.1%) 
117,251 (76.5%) 
 
67,820 (44.3%) 
27,370 (17.9%) 
58,067 (37.9%) 
 
104,258 (68.0%) 
23,526 (15.4%) 
25,473 (16.6%) 
 
70,830 (46.2%) 
20,526 (13.4%) 
61,901 (40.4%) 
 
151,308 (98.7%) 
1,949 (1.3%) 
33,973 (86.5%) 
 
9,075 (23.1%) 
6,766 (17.2%) 
23.421 (59.7%) 
 
22,549 (57.4%) 
6,861 (17.5%) 
9,852 (25.1%) 
 
12,514 (31.9%) 
4,292 (10.9%) 
22,456 (57.2%) 
 
38,283 (97.5%) 
979 (2.5%) 
Serum Lactate mmol/L 
Mean (SD) 
Median (IQR) 
>2mmol/L N (%) 
 
3.0 (3.0) 
2.0 (1.3 – 3.5) 
89,435 (48.1%) 
 
3.0 (3.0) 
2.0 (1.3 – 3.5) 
89,613 (47.9%) 
 
3.4 (3.3) 
2.3 (1.4 – 4.2) 
79,432 (54.7%) 
 
5.9 (4.0) 
4.5 (3.0 – 7.5) 
39,262 (100%) 
Outcomes 
ICU mortality N (%) 
ICU LOS (days) Median (IQR) 
Readmissions N (%) 
Hospital mortality N (%) 
 
43,183 (21.8%) 
3.8 (1.7 – 8.0) 
15,856 (8.0%) 
56,394 (31.1%) 
 
44,130 (22.4%) 
3.8 (1.8 – 8.1) 
15,563 (7.9%) 
57,524 (31.8%) 
 
39,294 (25.6%) 
4.0 (1.8 – 8.8) 
11,482 (7.5%) 
49,656 (35.1%) 
 
18,338 (46.7%) 
5.2 (1.8 – 12.0) 
2,243 (5.7%)  
20,457 (55.5%) 
Risk adjusted OR (95% CI)#  
p-value 
DAUC 
|DBIC| 
Brier Score 
1.16 (1.13 – 1.20) 
p<0.001 
0.83 vs 0.83 
350.51 
0.120 
1.16 (1.13 – 1.20)  
p<0.001 
0.83 vs 0.83 
342.68 
0.120 
1.30 (1.26 – 1.34)  
p<0.001 
0.83 vs 0.83 
1067.56 
0.120 
2.44 (2.32 – 2.57)  
p<0.001 
0.83 vs 0.83 
5086.11 
0.119 
 
  
22 
22 
Figure Legends 
Figure-1: Flow diagram and Venn diagrams showing the relationship between Sepsis-3 
and Sepsis-2 populations. 
Amongst the 205,632 sepsis patients, N=8,481 (4.1%) were identified only by Sepsis-2 
Severe Sepsis and N=7,899 (3.8%) were identified only by Sepsis-3 Sepsis 
operationalisation. There were N=39,262 Sepsis-3 Septic shock cases and N=153,257 
Sepsis-2 Septic Shock cases. Amongst the 153,623 septic shock cases identified by either of 
the definitions, N=114727 were identified only by Sepsis-2 Septic shock and N=366 were 
identified by only by Sepsis-2 Septic shock operationalisation. Please note that Sepsis-2 
septic shock, and Sepsis-3 septic shock populations are included within the broader Sepsis-2 
severe sepsis and Sepsis-3 sepsis categories respectively. 
 
Figure-2: Comparison of the distribution of APACHE II scores and Kaplan-Meier 
survival curves between old and new sepsis populations 
The APACHE II score distributions in Sepsis-2 severe sepsis and Sepsis-3 sepsis (A) and 
Sepsis-2 septic shock and Sepsis-3 septic shock (B), similar Kaplan-Meier survival curves for 
acute hospital mortality censored at 90 days for Sepsis-2 severe sepsis and Sepsis-3 sepsis 
(C) and significantly different Kaplan-Meier survival curves censored at 90 days for acute 
hospital mortality between Sepsis-2 septic shock and Sepsis-3 septic shock (D). 
 
Figure-3: Age and severe comorbidity-specific extrapolated population incidence of, 
and age-category specific crude acute hospital mortality from, Sepsis-2 severe sepsis 
Sepsis-2 septic shock, Sepsis-3 sepsis and Sepsis-3 septic shock 
P<0.001 for trends in age-specific mortality rates for Sepsis-2 severe sepsis (A), Sepsis-2 
septic shock (B), Sepsis-3 sepsis (C) and Sepsis-3 septic shock (D). Admissions without 
severe comorbidity were more common than admissions with severe comorbidities as defined 
using APACHE II definitions. PMH = past medical history of severe comorbidity 
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Figure-4: Comparison of the trends in extrapolated numbers of ICU admissions and 
numbers per 100,000 population between old and new sepsis populations. 
The extrapolated number of ICU admissions for Sepsis-2 severe sepsis and Sepsis-3 sepsis 
(A) and for Sepsis-2 septic shock and Sepsis-3 septic shock (B); the extrapolated numbers 
per 100,000 population person-years for Sepsis-2 severe sepsis and Sepsis-3 sepsis (C) and 
for Sepsis-2 septic shock and Sepsis-3 septic shock (D). 
 
